Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited has successfully completed an oversubscribed $3.9 million entitlement offer, with the raised funds set to advance the XanaMIA trial for Alzheimer’s treatment and general working capital. The offer saw a high demand with applications for additional shares reaching 1.8 times the available amount, indicating strong investor confidence. The new shares and options have been issued, with trading set to begin the following day on the ASX.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
